LncRNA FUNDC2P4 down-regulation promotes epithelial–mesenchymal transition by reducing E-cadherin expression in residual hepatocellular carcinoma after insufficient radiofrequency ablation

References

• Siegel RL, Miller KD, Jemal A. (2016). Cancer statistics, 2016. CA Cancer J Clin 66:7–30.
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. (2016). Cancer statistics in China, 2015. CA Cancer J Clin 66:115–32.
   PubMed Web of Science ®Google Scholar
• Zhang N, Wang L, Chai ZT, et al. (2014). Incomplete radiofrequency ablation enhances invasiveness and metastasis of residual cancer of hepatocellular carcinoma cell HCCLM3 via activating beta-catenin signaling. PLoS One 9:e115949.
   PubMed Web of Science ®Google Scholar
• Teng W, Liu KW, Lin CC, et al. (2015). Insufficient ablative margin determined by early computed tomography may predict the recurrence of hepatocellular carcinoma after radiofrequency ablation. Liver Cancer 4:26–38.
   PubMed Web of Science ®Google Scholar
• Poch FG, Rieder C, Ballhausen H, et al. (2016). The vascular cooling effect in hepatic multipolar radiofrequency ablation leads to incomplete ablation ex vivo. Int J Hypertherm 32:749–56.
   PubMed Web of Science ®Google Scholar
• Zheng XW, Zhao YF, Tang Z, et al. (2016). [Efficiency and influencing factors of ultrasound-guided radiofrequency ablation as treatment in hepatic malignant tumors]. Zhonghua gan zang Chin J Hepatol 24:69–73.
   PubMedGoogle Scholar
• Donadon M, Solbiati L, Dawson L, et al. (2016). Hepatocellular carcinoma: the role of interventional oncology. Liver Cancer 6:34–43.
   PubMed Web of Science ®Google Scholar
• Ruzzenente A, Manzoni GD, Molfetta M, et al. (2004). Rapid progression of hepatocellular carcinoma after radiofrequency ablation. World J Gastroenterol 10:1137–40.
   PubMed Web of Science ®Google Scholar
• Ke S, Ding XM, Kong J, et al. (2010). Low temperature of radiofrequency ablation at the target sites can facilitate rapid progression of residual hepatic VX2 carcinoma. J Transl Med 8:73.
   PubMed Web of Science ®Google Scholar
• Kang TW, Lim HK, Cha DI. (2017). Aggressive tumor recurrence after radiofrequency ablation for hepatocellular carcinoma. Clin Mol Hepatol 23:95–101.
   PubMed Web of Science ®Google Scholar
• Chaffer CL, Weinberg RA. (2011). A perspective on cancer cell metastasis. Science 331:1559–64.
   PubMed Web of Science ®Google Scholar
• Yang J, Weinberg RA. (2008). Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14:818–29.
   PubMed Web of Science ®Google Scholar
• Lamouille S, Xu J, Derynck R. (2014). Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15:178–96.
   PubMed Web of Science ®Google Scholar
• Heery R, Finn SP, Cuffe S, et al. (2017). Long non-coding RNAs: key regulators of epithelial-mesenchymal transition, tumour drug resistance and cancer stem cells. Cancers (Basel) 9:38.
   PubMed Web of Science ®Google Scholar
• Serrano-Gomez SJ, Maziveyi M, Alahari SK. (2016). Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. Mol Cancer 15:18.
   PubMed Web of Science ®Google Scholar
• Dong S, Kong J, Kong F, et al. (2013). Insufficient radiofrequency ablation promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through Akt and ERK signaling pathways. J Transl Med 11:273.
   PubMed Web of Science ®Google Scholar
• Yoshida S, Kornek M, Ikenaga N, et al. (2013). Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma. Hepatology 58:1667–80.
   PubMed Web of Science ®Google Scholar
• Wang-Yuan Z, Jiang-Zheng Z, Lu YD, et al. (2016). Clinical efficacy of metronomic chemotherapy after cool-tip radiofrequency ablation in the treatment of hepatocellular carcinoma. Int J Hypertherm 32:193–8.
   PubMed Web of Science ®Google Scholar
• Schmitt AM, Chang HY. (2016). Long noncoding RNAs in cancer pathways. Cancer Cell 29:452–63.
   PubMed Web of Science ®Google Scholar
• Yu FJ, Zheng JJ, Dong PH, et al. (2015). Long non-coding RNAs and hepatocellular carcinoma. Mol Clin Oncol 3:13–17.
   PubMedGoogle Scholar
• Yuan JH, Yang F, Wang F, et al. (2014). A long noncoding RNA activated by TGF-beta promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell 25:666–81.
   PubMed Web of Science ®Google Scholar
• Li T, Xie J, Shen C, et al. (2016). Upregulation of long noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma. Oncogene 35:1575–84.
   PubMed Web of Science ®Google Scholar
• Wang TH, Lin YS, Chen Y, et al. (2015). Long non-coding RNA AOC4P suppresses hepatocellular carcinoma metastasis by enhancing vimentin degradation and inhibiting epithelial-mesenchymal transition. Oncotarget 6:23342–57.
   PubMedGoogle Scholar
• Li SP, Xu HX, Yu Y, et al. (2016). LncRNA HULC enhances epithelial-mesenchymal transition to promote tumorigenesis and metastasis of hepatocellular carcinoma via the miR-200a-3p/ZEB1 signaling pathway. Oncotarget 7:42431–46.
   PubMed Web of Science ®Google Scholar
• Obara K, Matsumoto N, Okamoto M, et al. (2008). Insufficient radiofrequency ablation therapy may induce further malignant transformation of hepatocellular carcinoma. Hepatol Int 2:116–23.
   PubMed Web of Science ®Google Scholar
• Shiina S, Tateishi R, Arano T, et al. (2012). Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 107:569–77.
   PubMed Web of Science ®Google Scholar
• Wang P, Xue Y, Han Y, et al. (2014). The STAT3-binding long noncoding RNA lnc-DC controls human dendritic cell differentiation. Science 344:310–13.
   PubMed Web of Science ®Google Scholar
• Sun CC, Li SJ, Li G, et al. (2016). Long intergenic noncoding RNA 00511 acts as an oncogene in non-small-cell lung cancer by binding to EZH2 and suppressing p57. Mol Ther Nucleic Acids 5:e385.
   PubMedGoogle Scholar
• Li G, Warden C, Zou Z, et al. (2013). Altered expression of polycomb group genes in glioblastoma multiforme. PLoS One 8:e80970.
   PubMed Web of Science ®Google Scholar
• Forzati F, Federico A, Pallante P, et al. (2012). CBX7 is a tumor suppressor in mice and humans. J Clin Investig 122:612–23.
   PubMed Web of Science ®Google Scholar
• Karamitopoulou E, Pallante P, Zlobec I, et al. (2010). Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer. Eur J Cancer (Oxford, England: 1990) 46:1438–44.
   PubMed Web of Science ®Google Scholar
• Hinz S, Kempkensteffen C, Christoph F, et al. (2008). Expression parameters of the polycomb group proteins BMI1, SUZ12, RING1 and CBX7 in urothelial carcinoma of the bladder and their prognostic relevance. Tumor Biol 29:323–9.
   PubMed Web of Science ®Google Scholar
• Pallante P, Federico A, Berlingieri MT, et al. (2008). Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. Cancer Res 68:6770–8.
   PubMed Web of Science ®Google Scholar
• Mansueto G, Forzati F, Ferraro A, et al. (2010). Identification of a new pathway for tumor progression: MicroRNA-181b up-regulation and CBX7 down-regulation by HMGA1 protein. Genes Cancer 1:210–24.
   PubMedGoogle Scholar
• Pallante P, Terracciano L, Carafa V, et al. (2010). The loss of the CBX7 gene expression represents an adverse prognostic marker for survival of colon carcinoma patients. Eur J Cancer (Oxford, England: 1990) 46:2304–13.
   PubMed Web of Science ®Google Scholar
• Pallante P, Forzati F, Federico A, et al. (2015). Polycomb protein family member CBX7 plays a critical role in cancer progression. Am J Cancer Res 5:1594–601.
   PubMed Web of Science ®Google Scholar
• Ni S, Wang H, Zhu X, et al. (2017). CBX7 suppresses cell proliferation, migration, and invasion through the inhibition of PTEN/Akt signaling in pancreatic cancer. Oncotarget 8:8010–21.
   PubMedGoogle Scholar
• Federico A, Pallante P, Bianco M, et al. (2009). Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein. Cancer Res 69:7079–87.
   PubMed Web of Science ®Google Scholar
• Sepe R, Formisano U, Federico A, et al. (2015). CBX7 and HMGA1b proteins act in opposite way on the regulation of the SPP1 gene expression. Oncotarget 6:2680–92.
   PubMedGoogle Scholar
• Onder TT, Gupta PB, Mani SA, et al. (2008). Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 68:3645–54.
   PubMed Web of Science ®Google Scholar
• Chun HW, Hong R. (2016). Significance of the hedgehog pathway-associated proteins Gli-1 and Gli-2 and the epithelial-mesenchymal transition-associated proteins Twist and E-cadherin in hepatocellular carcinoma. Oncol Lett 12:1753–62.
   PubMed Web of Science ®Google Scholar
• Hazan RB, Qiao R, Keren R, et al. (2004). Cadherin switch in tumor progression. Ann NY Acad Sci 1014:155–63.
   PubMed Web of Science ®Google Scholar
• Zeisberg M, Neilson EG. (2009). Biomarkers for epithelial-mesenchymal transitions. J Clin Investig 119:1429–37.
   PubMed Web of Science ®Google Scholar